share_log

CSL and Arcturus Therapeutics Announce Nature Communications Has Published Pivotal Data Demonstrating Efficacy And Tolerability Of COVID-19 Vaccine

Benzinga ·  May 20 20:42
  • Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan.
  • These results add to recently published data on ARCT-154 demonstrating superior immunogenicity to Omicron BA 4/5 compared to conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating longer duration of immunity compared to traditional COVID-19 mRNA vaccine booster.

KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ -- Global biotechnology leader CSL ((ASX:CSL, OTC:CSLLY) and Arcturus Therapeutics (NASDAQ:ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment